Rofecoxib is a nonsteroidal antiinflammatory drug (NSAID) that selectively inhibits cyclooxgenase-2 (Cox-2), which was used in the therapy of chronic arthritis and mild-to-moderate musculoskeletal pain. Rofecoxib was withdrawn in 2004 because of an association with an increase in cardiovascular events with its long term use. Rofecoxib had also been linked transient serum aminotransferase elevations during therapy and to rare instances of idiosyncratic drug induced liver disease. It is grouped under the following drug class(es): Cyclooxygenase‑2 (COX‑2) Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAID). Its therapeutic use is listed as analgesics, anti-inflammatories and antirheumatic agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Vioxx, Ceoxx and MK 966. Its PubChem CID is 5090.
Rofecoxib
| CAS No | 162011-90-7 |
|---|---|
| Molecular Formula | C17H14O4S |
| Molecular Weight | 314.4 g/mol |
| Synonyms | 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rofecoxib is a nonsteroidal antiinflammatory drug (NSAID) that selectively inhibits cyclooxgenase-2 (Cox-2), which was used in the therapy of chronic arthritis and mild-to-moderate musculoskeletal pain.
The listed CAS number is 162011-90-7.
The listed molecular formula is C17H14O4S.
The listed molecular weight is 314.4 g/mol.
3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one.
The source lists Vioxx, Ceoxx and MK 966.